Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19, and CD3, into first-in-human trials for autoimmune disease.
Samantha Truex, Oblenio Bio CEO (courtesy Oblenio Bio)
June 25, 2026 06:00 AM EDT
FinancingStartups
Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures
Ayisha Sharma
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Beeline ups its Series A round for immune drug work
Bionyra brings in $165M for next-generation immune drugs
AbbVie's Big Immunology Acquisition
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
Ophthalmology venture grabs investors’ attention, raises $330 million
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a…
Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of…
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common…
